BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 15538242)

  • 1. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.
    Daneshmand S; Quek ML; Stein JP; Lieskovsky G; Cai J; Pinski J; Skinner EC; Skinner DG
    J Urol; 2004 Dec; 172(6 Pt 1):2252-5. PubMed ID: 15538242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
    Bader P; Burkhard FC; Markwalder R; Studer UE
    J Urol; 2003 Mar; 169(3):849-54. PubMed ID: 12576797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy.
    von Bodman C; Godoy G; Chade DC; Cronin A; Tafe LJ; Fine SW; Laudone V; Scardino PT; Eastham JA
    J Urol; 2010 Jul; 184(1):143-8. PubMed ID: 20478587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.
    Briganti A; Karnes JR; Da Pozzo LF; Cozzarini C; Gallina A; Suardi N; Bianchi M; Freschi M; Doglioni C; Fazio F; Rigatti P; Montorsi F; Blute ML
    Eur Urol; 2009 Feb; 55(2):261-70. PubMed ID: 18838212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nondissection of pelvic lymph nodes does not influence the results of perineal radical prostatectomy in selected patients.
    Salomon L; Hoznek A; Lefrère-Belda MA; Bellot J; Chopin DK; Abbou CC
    Eur Urol; 2000 Mar; 37(3):297-300. PubMed ID: 10720855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Outcome after radical prostatectomy with extended pelvic lymphadenectomy for untreated high-risk clinically localized prostate cancer].
    Tsurusaki T; Yamasaki Y; Maruta S
    Nihon Hinyokika Gakkai Zasshi; 2013 May; 104(3):496-504. PubMed ID: 23819361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Mortality in Patients with Positive Lymph Nodes at the Time of Radical Prostatectomy.
    Froehner M; Koch R; Farahzadi S; Heberling U; Borkowetz A; Twelker L; Baretton GB; Wirth MP; Thomas C
    Urol Int; 2019; 103(4):427-432. PubMed ID: 31661703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration.
    Bhindi B; Rangel LJ; Mason RJ; Gettman MT; Frank I; Kwon ED; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
    J Urol; 2017 Jul; 198(1):86-91. PubMed ID: 28130104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-institutional database.
    Schiavina R; Bianchi L; Borghesi M; Briganti A; Brunocilla E; Carini M; Terrone C; Mottrie A; Dente D; Gacci M; Gontero P; Gurioli A; Imbimbo C; La Manna G; Marchioro G; Milanese G; Mirone V; Montorsi F; Morgia G; Munegato S; Novara G; Panarello D; Porreca A; Russo GI; Serni S; Simonato A; Urzì D; Verze P; Volpe A; Martorana G
    Int J Urol; 2016 Dec; 23(12):1000-1008. PubMed ID: 27620370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer.
    Carlsson SV; Tafe LJ; Chade DC; Sjoberg DD; Passoni N; Shariat SF; Eastham J; Scardino PT; Fine SW; Touijer KA
    J Urol; 2013 Apr; 189(4):1314-8. PubMed ID: 23085057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
    Amiel T; Würnschimmel C; Heck M; Horn T; Nguyen N; Budäus L; Knipper S; Wenzel M; Rauscher I; Eiber M; Wang H; Maurer T
    J Urol; 2021 Jun; 205(6):1663-1670. PubMed ID: 33535796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy.
    Tilki D; Mandel P; Seeliger F; Kretschmer A; Karl A; Ergün S; Seitz M; Stief CG
    J Urol; 2015 Feb; 193(2):484-90. PubMed ID: 25180792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
    Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
    Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography.
    Karnes RJ; Murphy CR; Bergstralh EJ; DiMonte G; Cheville JC; Lowe VJ; Mynderse LA; Kwon ED
    J Urol; 2015 Jan; 193(1):111-6. PubMed ID: 25150640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.